Updated on 16 August 2015
Over the past few years, Asian lifescience sector has witnessed rapid growth and development making it a hot-bed for investors. Asian healthcare sector is roughly growing at a rate of 15 percent per annum which is faster than the US and Europe.
The continent represents nearly 40 percent of the world's population and 50 percent of the world's disease burden, thus offering opportunities for lifescience companies and investors to cash-in on the potential of these emerging markets.
Rising income levels, an ageing population, increasing prevalence and awareness of lifestyle diseases have led to a strong demand for health-care services, garnering the attention of lifescience companies and venture capitalists. Mr Abrar Mir, managing partner, Quadria Capital, said, "Asia has a very large qualified scientific talent, geography of much lower costs in comparison to the US, and high quality technology, making Asia a great destination for lifescience investments."
Long a hub of innovation, Japan has always led the way for biotechnology development and investments in Asia. China, South Korea and India with their huge population and healthcare challenges are emerging as biotech clusters and are successful in attracting the attention of venture capitalists.
New entrepreneurship communities have also emerged in Malaysia and Indonesia. The implementation of Universal Health Coverage in Indonesia has spurred the demand for quality healthcare services in the country, thus attracting investments from companies and investors alike. Australia, too, is an emerging market for health opportunities and is considered as a global leader for e-health. It is one of the very few countries that has integrated e-health into its health systems. Taiwan has exhibited very strong medical devices R&D capability that attracts investment opportunities. E-health is considered as one of the highlights by government in Taiwan and it has set funding to attract foreign medical devices & e-health companies to set up in Taiwan.